Skip to content
Stomach Cancer Surgery - Gastric Cancer Surgery
General Surgery

Stomach Cancer Surgery - Gastric Cancer Surgery

About This Department

German investigators randomly assigned 716 patients either to the chemotherapy regimen that had been standard for a decade or to a newer four-drug combination given before and after surgery, and median survival went from 35 months to 50. Nothing that happened in the operating room accounted for that. Stomach cancer surgery is one of the few cancer operations where the decisions made around the surgery have moved outcomes further than the decisions made during it, and this page is arranged to reflect that.

Free consultation

Find out what should happen before any operation

Send the endoscopy report with the biopsy result and the exact tumor location, the staging scans of chest, abdomen and pelvis with their written reports, any HER2 or mismatch repair result, your recent blood results including hemoglobin and albumin, your weight now and six months ago, and your medication list. A surgeon and a medical oncologist read the file together and tell you whether chemotherapy should come first, whether a staging laparoscopy is needed, and how much stomach is likely to be removed. No fee, no obligation, and a coordinator replies in your own language, usually within the same working day.

The four decisions

Everything on this page belongs to one of four questions, and they are answered in this order rather than the order patients usually ask them in.

  • Does treatment start with drugs or with surgery? For anything beyond the earliest tumors, chemotherapy before and after the operation is now standard in Europe, and the trial evidence behind that is stronger than the evidence behind any surgical refinement of the last twenty years.
  • How much stomach comes out? Total or partial, and that is decided by where the tumor sits rather than by how aggressive anybody wants to be. It is the single decision that most changes your life afterwards.
  • Where does the lymph node clearance stop? The argument between a limited and an extended clearance ran for thirty years, produced three randomized trials with different answers, and has settled in a way worth understanding.
  • Keyhole, open or robotic? Well studied for early tumors and now well studied for advanced ones too, with several thousand patients randomized. This matters for your fortnight and very little for your cancer.
  • One thing sits underneath all four. Where the operation is done. In Swiss national data covering 4,404 gastric cancer resections, postoperative death fell from 4.9 percent in low volume hospitals to 3.3 percent in high volume ones, with an adjusted odds ratio of 0.68 and a confidence interval of 0.48 to 0.98.

Before anything is removed

Looking inside before committing to an operation

Scans miss small deposits on the lining of the abdomen, and those deposits change the whole plan. A short keyhole look under anesthetic, with fluid washed into the abdomen and examined for cancer cells, is how that is checked before anybody commits to a major resection. Across 156 patients having a staging laparoscopy, visible disease was found in 38 of them, meaning 24 percent, and among the 118 whose laparoscopy looked clean, the washings still found cancer cells in 8. That is the value of the procedure stated plainly, which is that roughly a quarter of people thought to be operable on scans are not, and finding that out through a keyhole is far better than finding it out through a full incision. Cells in the washings without visible disease is a genuinely difficult situation, and a Japanese study of 100 such patients found that having chemotherapy was strongly associated with longer survival while having the stomach removed was not significantly so, which is an argument for treating first and deciding about surgery afterwards.

Chemotherapy before the operation

A British trial randomized 503 patients to three cycles of chemotherapy before surgery and three after, or to surgery alone, and five year survival was 36 percent against 23 percent, with a hazard ratio for death of 0.75 and a confidence interval of 0.60 to 0.93. Postoperative complications occurred in 46 percent against 45 percent, so the drugs did not make the operation more dangerous. A German trial then compared that regimen against a newer four-drug combination in 716 patients and found median survival of 50 months against 35, with a hazard ratio of 0.77 and a confidence interval of 0.63 to 0.94, and with serious side effects and hospitalizations for toxicity almost identical between the two arms. Those two results, taken together, are why an operation offered without any discussion of chemotherapy first should prompt a question rather than a booking, and the question is simply whether your case has been through a meeting where an oncologist was present.

How much stomach

Where the tumor sits decides this, and the decision is largely made for the surgeon rather than by them. An Italian trial randomized 618 patients with tumors in the lower stomach to a partial or a total removal and found five year survival of 65.3 percent against 62.4 percent, which met their statistical test for equivalence. Since the two operations cure equally well when both are possible, the smaller one wins on everything else.

Wide table ahead. On a narrow screen it scrolls sideways instead of shrinking, so swipe or drag it.

The operations for stomach cancer, and what each leaves you with
Operation When it is used What you are left with
Endoscopic resection The earliest tumors, lifted out through the scope with no incision at all and no lymph node clearance. A whole stomach. In one matched comparison of 117 pairs, five year survival was 96.5 against 99.1 percent with no significant difference, though disease-free survival was lower at 90.3 against 98.0 percent.
Distal or subtotal gastrectomy Tumors in the lower two thirds, where enough clearance can be left above the tumor. The upper stomach and its reservoir function. Less weight loss and easier eating than a total removal, and the operation this page's evidence mostly concerns.
Total gastrectomy Tumors high in the stomach, diffuse tumors spreading through the wall, and anything where a partial removal cannot reach clear tissue. No stomach. The small bowel is joined directly to the esophagus, and eating becomes a set of small meals rather than three normal ones.
Proximal gastrectomy Selected early tumors at the top of the stomach, where the lower part can be spared. The lower stomach. In 506 patients with stage I upper-stomach cancer it gave significantly less anemia and vitamin B12 deficiency than a total removal, with comparable cancer outcomes.
Prophylactic total gastrectomy Carriers of an inherited gene fault, with no cancer diagnosed. Covered further down this page. The same anatomy as a total gastrectomy for cancer, chosen deliberately by somebody who feels perfectly well.

One old rule deserves qualifying. Surgeons were long taught to take a fixed margin of normal stomach above the tumor, and for cancers at the top of the stomach that rule has not held up. Across 162 patients from seven American centers the average clear margin was 2.6 centimeters, and greater distance was not associated with either local recurrence or survival. What mattered was whether the margin was clear at all, and a margin containing cancer went with much heavier lymph node involvement, which suggests it was marking aggressive disease rather than causing it.

The operation itself

Three to five hours, depending on how much comes out and how the abdomen is entered.

1
The abdomen is inspected before anything is cut. The liver and the lining are examined for deposits that the scans could not see. Where a staging laparoscopy was already done, this is a confirmation rather than a discovery, which is one of the arguments for doing it separately and earlier.
2
The omentum comes off. The fatty apron hanging from the stomach is taken with the specimen as a matter of routine, because it drains the same territory. What is no longer taken routinely is the thin membrane behind it, for reasons in the lymph node section below.
3
The blood vessels are divided and the nodes come with them. Each artery feeding the stomach carries lymph nodes along its length, so dividing the vessels at their origin and clearing the tissue around them is the lymph node operation. The extent of that clearing is what the D1 and D2 argument is about.
4
The stomach is divided and a frozen section is often sent. A pathologist checks the cut edge while you are still asleep, so that more can be taken immediately if cancer reaches it. Ask whether this is routine practice, because it is the moment a positive margin becomes a fixable problem rather than a permanent one.
5
The digestive tract is rebuilt. After a partial removal the remaining stomach is joined either directly to the duodenum or to a loop of small bowel. After a total removal the esophagus is joined to the small bowel. That join, high in the abdomen and under tension from breathing, is the most fragile part of the whole operation.
6
A feeding tube is sometimes placed into the small bowel. A thin tube through the abdominal wall, used if eating is slow to restart or if a leak develops. It looks alarming and it is a sensible precaution rather than a sign that something has gone wrong.

How many lymph nodes

The argument that took thirty years

Japanese surgeons had long performed an extended clearance and reported better survival than Western centers, and two European trials set out to test whether the technique or the patients explained it. A British trial of 400 patients found five year survival of 33 percent after the extended operation and 35 percent after the limited one, with a hazard ratio for death of 1.10 and a confidence interval of 0.87 to 1.39. A Dutch trial of 711 patients undergoing curative surgery found the same at first, and then something changed with time. At fifteen years, overall survival was 29 percent after the extended clearance and 21 percent after the limited one, a difference that did not reach statistical significance, while death specifically from stomach cancer was 37 percent against 48 percent and local recurrence was 12 percent against 22 percent. The cost was heavy and it was paid early, with operative death of 10 percent against 4 percent, complications in 43 percent against 25 percent and reoperation in 18 percent against 8 percent. Almost all of that excess came from removing the spleen and part of the pancreas as part of the clearance, which is no longer done, and the modern conclusion is that an extended clearance performed without those additions, in a hospital that does many of them, is worth having.

Two things that were added and then taken back out

Surgery gets more radical until somebody randomizes it. Removing the spleen during a total gastrectomy was standard for years on the reasoning that nodes at its hilum could not otherwise be cleared, and a Japanese trial of 505 patients found five year survival of 75.1 percent with splenectomy and 76.4 percent without, formally confirming that keeping the spleen was not inferior while causing less bleeding and fewer complications. Stripping out the thin membrane behind the omentum, on the reasoning that stray cells might lurk there, was tested in 1,204 patients and stopped early for futility, with five year survival of 76.9 percent against 76.7 percent and a hazard ratio of 1.05. Pancreatic leaks were more common in the group that had the extra dissection, at 5 percent against 2 percent, and the five year follow-up confirmed both the absence of benefit and an excess of abdominal abscesses. Two large trials, two operations abandoned, and no patient worse off for the change.

Keyhole, open or robotic

Few operations have been tested this thoroughly. Korean, Japanese and Chinese groups have between them randomized several thousand patients, first for early cancers and then for advanced ones.

  • For early cancer, keyhole surgery is settled. A Korean trial of 1,416 patients found complications in 13.0 percent against 19.9 percent and wound problems in 3.1 percent against 7.7 percent, then reported five year survival of 94.2 percent against 93.3 percent. A Japanese trial of 921 patients found relapse-free survival at five years of 95.1 percent against 94.0 percent.
  • For advanced cancer it took longer and the answer is the same. A Korean trial of 1,050 patients found complications within 30 days in 16.6 percent against 24.1 percent and, at five years, overall survival of 88.9 percent against 88.7 percent. A Chinese trial of 1,056 patients found three year disease-free survival of 76.5 percent against 77.8 percent, meeting its threshold for non-inferiority.
  • Japanese investigators confirmed it independently. Among 502 patients with advanced disease, relapse-free survival at five years was 75.7 percent against 73.9 percent, with severe complications in 3.5 percent against 4.7 percent. Its authors stated that the result holds for qualified surgeons, which is a condition rather than a footnote.
  • Node counts come out the same either way. In the Korean advanced-cancer trial the average was 46.6 against 47.4, which is the measure that would show a compromised cancer operation and it shows nothing.
  • Robotic surgery has one randomized trial and it missed its target. Among 241 patients, abdominal infections were 6.2 percent robotic against 8.5 percent laparoscopic, which was the primary question and was not significant. Complications of any severity were lower with the robot as a secondary finding, and a pooled analysis of 5,447 patients found less bleeding and fewer overall complications with the robot alongside a longer operation and a higher cost.
  • Total gastrectomy by keyhole is less well evidenced. The published Korean work on it is a single-arm study of 160 patients rather than a randomized comparison, and it found narrowing at the join in 10.9 percent with one reconstruction method against 0 percent with another. Ask specifically about experience with the total operation, which is harder than the partial one.

Drugs around the surgery

What is standard depends heavily on where you are being treated, and the trials behind each approach were run in different populations. Knowing which one your plan comes from tells you a great deal.

Scroll this table sideways on a narrow screen. Swipe or drag it to reach the final column.

The trials behind chemotherapy for stomach cancer, and where each one applies
Approach What the trial found Where it is used
Chemotherapy before and after surgery In 503 patients, five year survival 36 against 23 percent, hazard ratio 0.75 with a confidence interval of 0.60 to 0.93, and no increase in surgical complications. Europe. This is the trial that made surgery-first the exception rather than the rule.
The newer four-drug regimen In 716 patients, median survival 50 months against 35, hazard ratio 0.77 with a confidence interval of 0.63 to 0.94, and serious side effects in 27 percent of both arms. Europe, for patients fit enough. It replaced the older regimen on this result.
Chemotherapy only after surgery In 1,035 patients across East Asia, five year disease-free survival 68 against 53 percent and overall survival 78 against 69 percent, with hazard ratios of 0.58 and 0.66. East Asia, after an extended node clearance. A different but equally valid strategy.
A single oral drug afterwards Five year survival 71.7 against 61.1 percent, hazard ratio 0.669 with a confidence interval of 0.540 to 0.828, in Japanese patients after an extended clearance. Japan. The drug is metabolized differently in East Asian and Western populations.
Chemotherapy with radiotherapy afterwards In 556 patients, median survival 36 months against 27, with severe toxicity in 41 percent and life-threatening toxicity in 32 percent. Mainly the United States, and mainly where the node clearance was limited.
Adding radiotherapy after a full clearance In 458 patients who had an extended clearance, adding radiotherapy gave a disease-free survival hazard ratio of 0.740 with a confidence interval of 0.520 to 1.050, which did not reach significance. Nowhere, as a routine. Radiotherapy adds less once the surgery has been thorough.

What can go wrong

Gastrectomy is major surgery in the upper abdomen and the list below is honest rather than comforting. Reading it beforehand is what lets you recognize a problem early.

Drag or swipe this table sideways on a small screen, since it scrolls instead of shrinking.

Complications after gastrectomy, when they appear and what is done
Problem How common and when What is done
Leak at the join to the esophagus 6.6 percent across 1,750 total gastrectomies in Italian centers, usually in the first week. A third needed reoperation, a quarter were managed by endoscopy or a drain and the rest settled with feeding through a tube. Stay went from 12 days to 27.
Infection deep in the abdomen 5.8 percent in a Japanese trial of 910 patients, most often in the first ten days. Antibiotics and a drain placed under scan guidance. Male sex and one type of reconstruction carried roughly double the odds.
Pancreatic leak 2 percent in the trial of standard surgery and 5 percent where extra dissection was added, in the first week. Drainage and time. This is the specific reason the extra dissection was abandoned.
Narrowing at the join Weeks to months. Reported at 10.9 percent with one reconstruction technique and 0 percent with another in a study of 160 patients. Stretching at endoscopy, often more than once. Rarely needs another operation.
Death within thirty days 3.3 percent in high volume Swiss hospitals and 4.9 percent in low volume ones. Under 1 percent in the modern Korean and Japanese trials. The gap between those figures is the argument for asking how many of these the hospital does each year.
Clots in the legs or lungs The first weeks, and raised by cancer, by abdominal surgery and by weight loss together. Blood thinning injections, often continued for weeks after discharge. A long flight taken early adds to the risk.

Recovery

Structured recovery programs have been tested here specifically, and across 25 randomized trials covering 2,809 patients they shortened hospital stay by 1.88 days, brought wind back 18 hours sooner and reduced complications with a relative risk of 0.55 and a confidence interval of 0.44 to 0.69.

  1. Day of surgery. Sitting out of bed, and sips of water if the surgeon allows. Pain relief is usually delivered through a fine tube in the back or by a pump you control yourself.
  2. Days one to three. Walking the corridor, breathing exercises taken seriously because chest infection is the commonest avoidable setback, and clear fluids in small amounts. Drains and lines start coming out.
  3. Days three to seven. The window when a leak declares itself, and the reason nobody sends you home early. A heart rate that climbs and stays up, worsening pain, a fever or new breathlessness all need reporting the same day.
  4. Around day five to seven, food restarts. Some units check the join with a swallow test first. Portions are tiny and that is the permanent new normal rather than a temporary restriction.
  5. Discharge at seven to twelve days. Longer after a total gastrectomy than a partial one, longer after an open operation than a keyhole one, and longer again if anything went wrong.
  6. Weeks two to eight. Tiredness out of proportion to what you did, weight still falling, and appetite that has not returned. All three are expected. Chemotherapy afterwards, where it is planned, usually starts around six to eight weeks.

Flying home

Two to three weeks after the operation, and later after a total gastrectomy or if anything was complicated. The number is set by the leak, which appears in the first week and which turned a twelve day stay into a twenty-seven day one in the Italian series, and by the pathology report, which takes one to two weeks and which decides what chemotherapy you need afterwards. Leaving before either is settled means leaving at exactly the wrong moment.

Three things belong in the conversation before you book a flight. Whether blood thinning injections continue and for how long, since cancer, abdominal surgery and weight loss stack on top of one another. Whether you are going home with a feeding tube, and if so who will manage it and where the supplies come from. And whether your own oncologist has an appointment booked already, because the gap between surgery and starting chemotherapy is where cross-border care most often falls apart, and six to eight weeks disappears quickly when nobody has arranged anything.


Eating, and dumping

The stomach holds food back and releases it slowly. Take it away, or take away the valve at its outlet, and food arrives in the small bowel all at once. The consequences of that have a name and they are far more common than most patients are warned about.

Among 1,153 patients surveyed after gastrectomy, 67.6 percent reported early dumping, which is cramping, nausea, flushing, a racing heart and sometimes diarrhea within half an hour of eating. Late dumping, which is sweating, shaking and weakness one to three hours after a meal as blood sugar falls, affected 38.4 percent.

Those figures come from a questionnaire rather than from formal testing, so they capture symptoms as patients experience them, which is arguably the more useful measure. The same study found what reduced the risk, and it is a short and practical list. Losing less weight after the operation, being older, having the valve at the stomach outlet preserved, and having the reconstruction done in one particular way rather than another all went with less early dumping. Nothing on that list is under your control except the first, which is the strongest argument on this page for taking the eating advice seriously from the first week rather than the third month. Dumping is also treatable when it persists, with dietary changes first and medication afterwards for the minority in whom that is not enough, so a patient who has been living with it for a year without mentioning it has usually been suffering unnecessarily. Say it out loud at the first follow-up appointment.

The first six months

Weight loss after gastrectomy is expected, and how much you lose is partly decided by how you eat in the first weeks. Six habits do most of the work.

1
Six small meals rather than three. A quarter to a third of what you used to eat, every two to three hours. This is not a phase to get through, and for a total gastrectomy it is permanent.
2
Drink between meals instead of during them. Fluid takes up the small space you have and speeds food through it. Half an hour either side of eating is the usual advice and it makes a noticeable difference to dumping.
3
Protein at every meal, sugar at none. Sweet drinks and sugary food are the classic trigger for early dumping, and protein is what protects muscle while your weight is falling. Both of those matter more than the total calorie count.
4
Sit up for half an hour afterwards. Lying down after eating causes reflux into the esophagus, which is unprotected once the stomach is gone. Raising the head of the bed helps at night for the same reason.
5
Weigh yourself weekly and write it down. A steady fall that levels off after three to six months is expected. One that keeps going, or that resumes after settling, needs investigating rather than accepting.
6
See a dietitian, and see them more than once. Ask for the appointment before you leave the hospital. This is the single most useful referral after gastrectomy and it is the one most often left to the patient to chase.

What stops being absorbed

The stomach does chemistry as well as storage, and losing it has consequences that appear months or years later rather than immediately.

Vitamin B12 needs replacing for life after a total gastrectomy
A protein made in the stomach lining is required to absorb it, and without a stomach no amount of dietary intake substitutes. Injections, usually every two or three months, are the standard answer. In 506 patients with early upper-stomach cancer, those who kept part of the stomach had significantly less anemia and B12 deficiency than those who did not.
Iron absorption falls too
Stomach acid converts iron into the form the gut can take up, and both partial and total gastrectomy reduce it. Anemia that develops a year or two after surgery is usually this rather than recurrence, though it should still be investigated properly rather than assumed.
Bone density falls measurably
A small study following 49 patients with stage I disease for an average of just under three years found bone density at the lumbar spine fell by 7.17 percent after gastrectomy against 3.30 percent after endoscopic treatment, and at the hip by 6.30 percent against 1.52 percent. That study had 49 patients in it, so treat the numbers as a signal rather than a precise rate, and treat the direction as settled.
What to ask for in follow-up
Blood counts, iron studies, vitamin B12, vitamin D and calcium at least yearly, and a bone density scan at some point after a total gastrectomy. None of that happens automatically in most systems, and all of it is cheap and treatable. Take the list to your own doctor rather than waiting to be offered it.

Spread to the lining

Stomach cancer spreads to the lining of the abdomen more readily than most cancers, and this is the situation where you are most likely to be offered something unproven. Three things are worth knowing before that conversation.

Chemotherapy delivered into the abdomen has one phase three trial and it missed
A Japanese trial gave 183 patients either chemotherapy partly into the abdominal cavity or the standard intravenous regimen. Median survival was 17.7 months against 15.2, with a hazard ratio of 0.72 and a probability value of 0.080, which failed its own threshold. A later analysis adjusting for the fact that the treated group had more fluid in the abdomen at the start gave a hazard ratio of 0.59, and that is a sensitivity analysis rather than the trial's result.
Heated chemotherapy at the time of surgery is a different thing again
It is offered in some centers for stomach cancer and this page found no completed randomized trial supporting it in that disease. Anybody presenting it to you as established should be asked which trial they are relying on, and the answer should be a named study with published results rather than a description of a center's own experience.
Cells in the washings without visible deposits is its own category
In 100 such patients, chemotherapy went with median survival of 23.0 months against 8.6 months without it, a large and highly significant difference, while removing the stomach did not reach significance at a hazard ratio of 0.677. That is an argument for treating first and reassessing, and it is why the washings are worth taking in the first place.
How to hold all of this
Peritoneal spread is not automatically the end of active treatment and it is also not a situation where an aggressive operation has been shown to help. The reasonable position is systemic treatment first, reassessment afterwards, and considerable caution about any surgical addition being presented with more confidence than its evidence supports.

The inherited kind

Why a healthy person has their stomach removed

A small proportion of stomach cancers run in families through a fault in a single gene, and the cancer it causes spreads through the stomach wall without forming a lump that endoscopy can find. Surveillance therefore does not work well, and carriers are offered removal of a healthy-looking stomach as prevention. It is one of the hardest decisions in surgery and the strongest justification for it comes from the pathology reports afterwards. Among 150 people who had this operation with no cancer diagnosed and no symptoms, the final examination found early cancer cells hiding in the stomach wall in 132 of them, which is 88.0 percent. Nobody in that series developed stomach cancer or died of it over a median of three years of follow-up. Read that 88 percent figure carefully, because it does not mean 88 percent of carriers would have gone on to develop a life-threatening cancer, and it does mean that the disease process was already underway in almost everybody who chose the operation. The decision is still a hard one and the pathology at least tells you it was not made on a hypothetical.

What it costs

The same series reported serious complications in 11.3 percent, with a leak at the join in 7.3 percent, and its authors said plainly that work is still needed on reducing the long-term burden of living without a stomach. Everything in the eating and absorption sections above applies to these patients too, and they are typically decades younger than the average person having this operation for cancer. If stomach cancer has affected two or more close relatives, particularly at a young age, or if any relative had the diffuse type, genetic counseling is the right next step rather than more frequent endoscopy. That referral is worth asking for by name, because it is rarely offered. A counselor will take a proper family history, explain what a test result would and would not tell you, and set out what surveillance exists for people who decide against surgery, and none of those three conversations happens well in a fifteen minute clinic appointment with a surgeon. Ask for it early.

Where you have it

Almost every trial on this page carries the same quiet condition. The Japanese advanced-cancer trial stated its result held for qualified surgeons. The Dutch trial's authors said their conclusion applied to an extended clearance performed in specialist centers. Swiss national data covering 4,404 gastric cancer resections found postoperative death fell from 4.9 percent in the lowest volume hospitals to 3.3 percent in the highest, with an adjusted odds ratio of 0.68 and a confidence interval of 0.48 to 0.98, and the same pattern held for esophageal, pancreatic and rectal surgery.

Set that against the modern trials, where thirty day mortality ran below 1 percent in Korean and Japanese centers doing very high numbers, and the size of the gap becomes clear. It is a bigger difference than any of the surgical refinements argued over in the rest of this page. Ask how many gastrectomies the hospital does in a year and how many the surgeon does personally. Both are facts, both are known, and a unit that will not answer has told you something by declining.


Questions to ask

Before you agree to anything

Whether chemotherapy should come before the operation, and if the answer is no, why your case differs from the trials that established it. Whether a staging laparoscopy with washings is planned, given that a quarter of patients thought operable on scans had visible disease at laparoscopy in one series. Whether the plan is a total or a partial removal, and what decides that in your case. Whether the lymph node clearance will be the extended one and whether the spleen will be kept, since keeping it was formally shown to be no worse in a trial of 505 patients. Whether the operation is planned as keyhole, and specifically how many total gastrectomies by keyhole the surgeon has done, because the evidence for the partial operation is far stronger than for the total one. How many gastrectomies the hospital does each year. And whether your case has been through a meeting with a surgeon, an oncologist, a radiologist and a pathologist present.

Before you leave the hospital

Ask for the operation note and the pathology report as documents rather than as a summary, and check that the pathology report states how much stomach was removed, whether the margins were clear, how many lymph nodes were examined and how many contained cancer. Ask what reconstruction was used, because it predicts dumping and it is the first thing a dietitian will want to know. Ask whether vitamin B12 injections start now and how often. Ask whether a feeding tube is going home with you and who manages it. Ask when chemotherapy should start and get that in writing to hand to your own oncologist. And ask for a dietitian appointment at home to be arranged before you fly, since it is the referral that changes the next six months most and the one nobody arranges for you. Ask for all of it on paper and in English, and check on the ward that the documents say what you were told in conversation, because a discharge summary that names the diagnosis without naming the operation and the reconstruction is common and is close to useless to whoever reads it next.

Reading a quote

No figure appears on this page, and for this operation a number quoted without a set of conditions attached is close to meaningless, because the same word covers an eight day stay and a four week one.

Seven things belong in writing. Which operation, named as total or distal. How many nights are budgeted and what an extra one costs. Whether a leak and its treatment are covered, given that a leak took the stay from 12 days to 27 in the Italian series. Whether the staging laparoscopy is included or billed separately. Whether pathology is inside the number. Whether chemotherapy before or after is inside it, alongside it, or expected at home. And what is excluded.

Your own file moves the total here more than in most operations. Whether the whole stomach comes out, whether chemotherapy is given first and where, whether a staging laparoscopy is done as a separate admission, and whether a feeding tube goes home with you are the four variables that decide the number. Packages published by Turkish hospitals and medical travel agencies generally include transfers, pre-operative testing, surgeon and anesthesia fees, the operating room, the planned nights, pathology, an interpreter and a review before departure, and generally exclude flights, insurance, chemotherapy, treatment of a complication, extra nights, feeding supplies and follow-up beyond the first weeks. Read what arrives against both lists rather than against the headline. A quote that answers every one of those seven points is usually from a unit that has thought about the pathway, and a quote that answers none of them has moved the whole of the financial risk onto you without saying so in writing.

Coming to Istanbul

Eighteen to twenty-four days covers assessment, the operation and a safe departure for somebody arriving with staging complete, and that is longer than for most operations on this site for reasons the first card explains.

Why the stay is longer than you expect
A leak at the join to the esophagus appears in the first week and is managed far better where the join was made. The pathology report that decides your chemotherapy takes one to two weeks. And eating has to be re-established before travel, which cannot be rushed. Where chemotherapy is planned first, that happens at home over several months and the surgical visit comes afterwards.
Send these things, in this order
The endoscopy report with the biopsy result and the exact tumor location, the staging scans with their written reports, any HER2 or mismatch repair result, your weight now and six months ago, recent blood results including hemoglobin and albumin, your medication list, and a note of any chemotherapy already given with the drug names and dates. That last item is the one most often left out and the one that changes the plan most.
What is arranged for you
One coordinator holds your file from the first message to discharge, and the international patients team works in English, Arabic, French, Russian, Serbian, Romanian and Spanish, with other languages arranged on request. Ask in your first message if you would prefer a female physician. Someone can stay overnight with you on the ward, where the rooms carry a companion bed, meals cover halal, vegetarian and diabetic diets, and a prayer room is available. The office books accommodation for both of you, arranges the airport transfer and daily transport, and prepares the appointment confirmation and the invitation letter naming the hospital and your treating doctor for a medical visa application, around ten days before travel.
What to take home
The operation note, the pathology report, the discharge summary, a written chemotherapy recommendation with a start date, a vitamin B12 plan, and a dietitian referral. Address the file to a named oncologist near you and book that appointment before you fly. Follow-up after returning home runs on a fixed pattern worth agreeing before you leave, which is a wound and weight review at around two weeks, an oncology appointment inside six weeks, blood tests covering iron, vitamin B12, vitamin D and calcium at least yearly, and a dietitian at three and six months. Your coordinator stays reachable on the same WhatsApp number afterwards, so a question about a wound, a feeding tube or a line in the report reaches somebody with your notes in front of them.

Stomach cancer surgery FAQ

Should chemotherapy come before the operation?
In Europe, usually yes for anything beyond the earliest tumors. A trial of 503 patients found five year survival of 36 against 23 percent with chemotherapy before and after surgery, and a later trial of 716 patients found a newer regimen gave median survival of 50 months against 35.
Will my whole stomach be removed?
Only if the tumor's position requires it. For tumors in the lower stomach a partial removal cured as well as a total one in a randomized trial of 618 patients, with five year survival of 65.3 against 62.4 percent, so the smaller operation is preferred wherever it is possible.
What is a D2 lymph node clearance and do I need one?
It is the more extensive of the two node clearances. At fifteen years the Dutch trial found death from stomach cancer in 37 percent after it against 48 percent after the limited version, and local recurrence in 12 against 22 percent. Its early mortality was much higher, and almost all of that came from removing the spleen and pancreas, which is no longer done.
Will my spleen be removed?
It should not be, unless the tumor involves it. A trial of 505 patients found five year survival of 76.4 percent when the spleen was kept and 75.1 percent when it was removed, formally confirming that preservation was not inferior, with less bleeding and fewer complications.
Is keyhole surgery safe for stomach cancer?
Yes, on several thousand randomized patients. For early cancer, five year survival was 94.2 against 93.3 percent in a trial of 1,416. For advanced cancer, five year survival was 88.9 against 88.7 percent in a trial of 1,050, with fewer complications in the keyhole group in both.
What will eating be like afterwards?
Six small meals a day rather than three, with drinks kept away from mealtimes. Among 1,153 patients surveyed after gastrectomy, 67.6 percent reported early dumping and 38.4 percent late dumping, so this is the normal experience rather than a complication, and a dietitian makes a real difference to it.
Will I need vitamin injections for the rest of my life?
After a total gastrectomy, yes, because vitamin B12 cannot be absorbed without a protein made in the stomach lining. Iron absorption also falls, and bone density fell measurably after gastrectomy in a small study of 49 patients. Ask for yearly blood tests covering all of it.
Can an early stomach cancer be removed without surgery?
Sometimes, through the endoscope. In a matched comparison of 117 pairs, five year survival was 96.5 percent after endoscopic removal and 99.1 percent after surgery with no significant difference, though disease-free survival was lower at 90.3 against 98.0 percent. Hospital stay was 3 days against 10.
Does hospital volume matter?
Measurably. In Swiss national data covering 4,404 gastric cancer resections, postoperative death was 4.9 percent in low volume hospitals against 3.3 percent in high volume ones, with an adjusted odds ratio of 0.68. In the modern Asian trials, thirty day mortality ran below 1 percent.
How long should I stay in Turkey?
Eighteen to twenty-four days. A leak at the join appears in the first week, the pathology report takes one to two weeks, and eating has to be re-established before a flight. All three argue against a short trip.

References

  1. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4), a randomised, phase 2/3 trial. The Lancet. 2019;393(10184):1948-1957.
  2. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. The New England Journal of Medicine. 2006;355(1):11-20.
  3. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJH. Surgical treatment of gastric cancer, 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. The Lancet Oncology. 2010;11(5):439-449.
  4. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P. Patient survival after D1 and D2 resections for gastric cancer, long-term results of the MRC randomized surgical trial. British Journal of Cancer. 1999;79(9-10):1522-1530.
  5. Degiuli M, Sasako M, Ponti A, Vendrame A, Tomatis M, Mazza C, Borasi A, Capussotti L, Fronda G, Morino M. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. British Journal of Surgery. 2014;101(2):23-31.
  6. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal versus total gastrectomy for gastric cancer, five-year survival rates in a multicenter randomized Italian trial. Annals of Surgery. 1999;230(2):170-178.
  7. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Crose N, Gennari L. Total versus subtotal gastrectomy, surgical morbidity and mortality rates in a multicenter Italian randomized trial. Annals of Surgery. 1997;226(5):613-620.
  8. Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, Nashimoto A, Ito S, Kaji M, Imamura H, Fukushima N, Fujitani K. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Annals of Surgery. 2017;265(2):277-283.
  9. Kurokawa Y, Doki Y, Mizusawa J, Terashima M, Katai H, Yoshikawa T, Kimura Y, Takiguchi S, Nishida Y, Fukushima N, Iwasaki Y, Kaji M, Hirao M, Katayama H, Sasako M. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001), a phase 3, open-label, randomised controlled trial. The Lancet Gastroenterology and Hepatology. 2018;3(7):460-468.
  10. Kurokawa Y, Doki Y, Mizusawa J, Yoshikawa T, Yamada T, Kimura Y, Takiguchi S, Nishida Y, Fukushima N, Cho H, Kaji M, Hirao M, Sasako M, Terashima M. Five-year follow-up of a randomized clinical trial comparing bursectomy and omentectomy alone for resectable gastric cancer (JCOG1001). British Journal of Surgery. 2022;110(1):50-56.
  11. Postlewait LM, Squires MH, Kooby DA, Poultsides GA, Weber SM, Bloomston M, Fields RC, Pawlik TM, Votanopoulos KI, Schmidt CR, Ejaz A, Acher AW. The importance of the proximal resection margin distance for proximal gastric adenocarcinoma, a multi-institutional study of the US Gastric Cancer Collaborative. Journal of Surgical Oncology. 2015;112(2):203-207.
  12. Kim W, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, Cho GS, Kim CY, Yang HK, Park DJ, Song KY, Lee SI, Ryu SY, Lee JH, Lee HJ. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer, short-term outcomes from a multicenter randomized controlled trial (KLASS-01). Annals of Surgery. 2016;263(1):28-35.
  13. Kim HH, Han SU, Kim MC, Kim W, Lee HJ, Ryu SW, Cho GS, Kim CY, Yang HK, Park DJ, Song KY, Lee SI, Ryu SY, Lee JH, Hyung WJ. Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among patients with stage I gastric cancer, the KLASS-01 randomized clinical trial. JAMA Oncology. 2019;5(4):506-513.
  14. Katai H, Mizusawa J, Katayama H, Takagi M, Yoshikawa T, Fukagawa T, Terashima M, Misawa K, Teshima S, Koeda K, Nunobe S, Fukushima N, Yasuda T, Asao Y, Fujiwara Y, Sasako M. Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer, JCOG0912. Gastric Cancer. 2017;20(4):699-708.
  15. Katai H, Mizusawa J, Katayama H, Morita S, Yamada T, Bando E, Ito S, Takagi M, Takagane A, Teshima S, Koeda K, Nunobe S, Yoshikawa T, Terashima M, Sasako M. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912). The Lancet Gastroenterology and Hepatology. 2020;5(2):142-151.
  16. Lee HJ, Hyung WJ, Yang HK, Han SU, Park YK, An JY, Kim W, Kim HI, Kim HH, Ryu SW, Hur H, Kong SH, Cho GS, Kim JJ, Park DJ, Ryu KW, Kim YW, Kim JW, Lee JH, Kim MC. Short-term outcomes of a multicenter randomized controlled trial comparing laparoscopic distal gastrectomy with D2 lymphadenectomy to open distal gastrectomy for locally advanced gastric cancer (KLASS-02-RCT). Annals of Surgery. 2019;270(6):983-991.
  17. Son SY, Hur H, Hyung WJ, Park YK, Lee HJ, An JY, Kim W, Kim HI, Kim HH, Ryu SW, Kim MC, Kong SH, Cho GS, Kim JJ, Park DJ, Ryu KW, Kim YW, Kim JW, Lee JH, Yang HK, Han SU. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer, 5-year outcomes of the KLASS-02 randomized clinical trial. JAMA Surgery. 2022;157(10):879-886.
  18. Yu J, Huang C, Sun Y, Su X, Cao H, Hu J, Wang K, Suo J, Tao K, He X, Wei H, Ying M, Hu W, Du X, Hu Y, Liu H, Zheng C, Li P, Xie J, Liu F, Li Z, Zhao G, Yang K, Liu C, Li H, Chen P, Ji J, Li G. Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer, the CLASS-01 randomized clinical trial. JAMA. 2019;321(20):1983-1992.
  19. Etoh T, Ohyama T, Sakuramoto S, Tsuji T, Lee SW, Yoshida K, Koeda K, Hiki N, Kunisaki C, Tokunaga M, Otsubo D, Takagane A, Misawa K, Kinoshita T, Cho H, Doki Y, Nunobe S, Shiraishi N, Kitano S. Five-year survival outcomes of laparoscopy-assisted vs open distal gastrectomy for advanced gastric cancer, the JLSSG0901 randomized clinical trial. JAMA Surgery. 2023;158(5):445-454.
  20. Yang HK, Hyung WJ, Han SU, Lee YJ, Park JM, Cho GS, Kwon OK, Kong SH, Kim HI, Lee HJ, Kim W, Ryu SW, Jin SH, Oh SJ, Ryu KW, Kim MC, Ahn HS, Park YK, Kim YH, Hwang SH, Kim JW, Kim JJ. Comparison of surgical outcomes among different methods of esophagojejunostomy in laparoscopic total gastrectomy for clinical stage I proximal gastric cancer, results of a single-arm multicenter phase II clinical trial in Korea, KLASS 03. Surgical Endoscopy. 2021;35(3):1156-1163.
  21. Ojima T, Nakamura M, Hayata K, Kitadani J, Katsuda M, Takeuchi A, Tominaga S, Nakai T, Nakamori M, Ohi M, Kusunoki M, Yamaue H. Short-term outcomes of robotic gastrectomy vs laparoscopic gastrectomy for patients with gastric cancer, a randomized clinical trial. JAMA Surgery. 2021;156(10):954-963.
  22. Yu X, Lei W, Zhu L, Qi F, Liu Y, Feng Q. Robotic versus laparoscopic distal gastrectomy for gastric cancer, a systematic review and meta-analysis. Asian Journal of Surgery. 2024.
  23. Jeon HK, Kim GH, Lee BE, Park DY, Song GA, Kim DH, Jeon TY. Long-term outcome of endoscopic submucosal dissection is comparable to that of surgery for early gastric cancer, a propensity-matched analysis. Gastric Cancer. 2018;21(1):133-143.
  24. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC), 5-year follow-up of an open-label, randomised phase 3 trial. The Lancet Oncology. 2014;15(12):1389-1396.
  25. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. Journal of Clinical Oncology. 2011;29(33):4387-4393.
  26. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. The New England Journal of Medicine. 2001;345(10):725-730.
  27. Park SH, Sohn TS, Lee J, Lim DH, Hong ME, Kim KM, Sohn I, Jung SH, Choi MG, Lee JH, Bae JM, Kim S, Kim ST, Park JO, Park YS, Lim HY, Kang WK. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer, final report of the Adjuvant Chemoradiotherapy in Stomach Tumors trial (ARTIST). Journal of Clinical Oncology. 2015;33(28):3130-3136.
  28. Wong J, Kelly KJ, Mittra A, Gonen M, Allen P, Fong Y, Coit D. Rt-PCR increases detection of submicroscopic peritoneal metastases in gastric cancer and has prognostic significance. Journal of Gastrointestinal Surgery. 2012;16(5):889-896.
  29. Kobayashi H, Honda M, Kawamura H, Takiguchi K, Muto A, Yamazaki S, Teranishi Y, Shiraso S, Kono K, Hori S, Kamiga T, Iwao T, Yamashita N. Clinical impact of gastrectomy for gastric cancer patients with positive lavage cytology without gross peritoneal dissemination. Journal of Surgical Oncology. 2022;125(4):615-620.
  30. Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y, Amagai K, Miwa H, Yamaguchi H, Yamaguchi T, Miyaji T, Kitayama J. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis, PHOENIX-GC trial. Journal of Clinical Oncology. 2018;36(19):1922-1929.
  31. Mine S, Sano T, Tsutsumi K, Murakami Y, Ehara K, Saka M, Hara K, Fukagawa T, Udagawa H, Katai H. Large-scale investigation into dumping syndrome after gastrectomy for gastric cancer. Journal of the American College of Surgeons. 2010;211(5):628-636.
  32. Song JH, Park SH, Cho M, Kim YM, Hyung WJ, Kim HI. Proximal gastrectomy is associated with lower incidence of anemia and vitamin B12 deficiency compared to total gastrectomy in patients with upper gastric cancer. Cancer Research and Treatment. 2025;57(1):174-185.
  33. Noh HM, Yoo JH, Jeong JY, Park YS. Bone mineral density after treatment for gastric cancer, endoscopic treatment versus gastrectomy. Medicine. 2018;97(1):e9582.
  34. Lee JH, Lee HJ, Choi YS, Kim TH, Huh YJ, Suh YS, Kong SH, Yang HK. Postoperative quality of life after total gastrectomy compared with partial gastrectomy, longitudinal evaluation by EORTC-OG25 and STO22. Journal of Gastric Cancer. 2016;16(4):230-239.
  35. Du N, Chen M, Shen Z, Li S, Chen P, Khadaroo PA, Mao D, Gu L. Comparison of quality of life and nutritional status of between Roux-en-Y and Billroth-I reconstruction after distal gastrectomy, a systematic review and meta-analysis. Nutrition and Cancer. 2020;72(5):849-857.
  36. Taki Y, Ito S, Mizusawa J, Yura M, Sato Y, Nomura T, Tsuda M, Omori T, Kunisaki C, Choda Y, Cho H, Hiki N, Boku N, Yoshikawa T, Katai H, Terashima M. Risk factors for abdominal surgical infectious complications after distal gastrectomy for gastric cancer, a post-hoc analysis of a randomized controlled trial (JCOG0912). European Journal of Surgical Oncology. 2024;50(3):107982.
  37. Trapani R, Rausei S, Reddavid R, Degiuli M. Risk factors for esophago-jejunal anastomosis leakage after total gastrectomy for cancer, a multicenter retrospective study of the Italian research group for gastric cancer. European Journal of Surgical Oncology. 2020;46(12):2243-2247.
  38. Guller U, Warschkow R, Ackermann CJ, Schmied B, Cerny T, Ess S. Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resection. Swiss Medical Weekly. 2017;147:w14473.
  39. Jin H, Song S, Lu T, Ma S, Wang Y, Fu L, Zhang G, Han X, Zhang L, Yang K, Cai H. The application of enhanced recovery after surgery in minimally invasive gastrectomy for gastric cancer, a meta-analysis of randomized controlled trials. Expert Review of Gastroenterology and Hepatology. 2022;16(11-12):1089-1100.
  40. Gallanis AF, Bowden C, Lopez R, Gamble LA, Samaranayake SG, Payne C, Snyder D, Fasaye GA, Joyce S, Broesamle R, Miao N, Miettinen M, Quezado M, Kim SA, Korman L, Heller T, Blakely AM, Hernandez JM, Davis JL. Lessons learned from 150 total gastrectomies for prevention of cancer. Journal of Gastrointestinal Surgery. 2025;29(1):101889.

Editor's note

Written by the Biruni Hospital medical editorial team. Reviewed by Assistant Professor Ertan EMEK, General Surgery.